����ӰԺ

The guideline supported by both European- and U.S.-based allergy organizations for allergy diagnosis includes a medical history, physical exam, and testing by either an in vitro method (such as 3gAllergy™) or an in vivo method (skin prick testing) to aid in diagnosis.³

Allergy testing can be performed by in vivo or in vitro methods. In vivo testing involves a skin prick test (SPT), which is often the first-line approach to determine the release of allergen-specific IgE antibodies. However, in vitro testing with highly purified allergens or recombinants can be used as an alternative or complementary diagnostic tool.⁴

Using a small serum sample, the laboratory measures specific IgE antibodies to many different allergens.

In vitro allergy blood testing supports improved patient outcomes:

• Convenient method for monitoring decreases in sensitization resulting from a medical intervention such as allergen avoidance
• Valuable diagnostic tool for following development and prognosis of sensitization in childhood
• Convenient for patients suffering from eczema, atopic dermatitis, and other skin conditions
• Practical for geriatric and pediatric patients affected by dermatographism
• Convenient method for pediatric and geriatric patients
• Easy to perform, with one simple blood draw to obtain multiple determinants
• Reduced risk of anaphylaxis
• No skin reactions
• No need to stop patient’s medications, as there is no interference with medications such as antihistamine H1 blockers, H2 antagonists, or tricyclic antidepressants⁶
• Good correlation with patient clinical history and skin tests⁷
• Readily available to primary care physicians

CCDs are carbohydrate structures present in many plants and insect allergens. These structures are not recognized by IgE antibodies specific to the allergen itself, but they can bind to IgE antibodies specific to CCDs. This can lead to false-positive results and clinical overestimation of a patient's sensitization to certain allergens.⁸

Therefore, it is important for laboratories performing in vitro testing to include controls that can detect the presence of CCD-specific IgE antibodies and interpret the results with caution, particularly when testing for allergens that are known to contain CCDs.^8,9

IMMULITE® 3gAllergy™ liquid allergen technology is a bead-based approach that reduces the need for additional allergy testing and the risk of false-positive results. 

The IMMULITE® 2000/XPi 3gAllergy™ – Allergen-specific IgE assay helps to enhance patient care with reliable results from a simple blood test that uses quality extracts thoroughly evaluated for potency and allergenic composition. The assay provides reliable results as an aid in the clinical diagnosis of IgE-mediated allergic disorders.

The 3gAllergy menu includes over 350 allergens, panels, and components across animals, drugs, dust, foods, grasses, insects, mites, molds, occupational, parasites, trees, and weeds.